StockNews.com Upgrades Repligen (NASDAQ:RGEN) to “Hold”

Repligen (NASDAQ:RGEN) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Monday.

A number of other research analysts have also recently commented on the company. Royal Bank of Canada increased their price target on Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a research note on Friday, February 21st. Evercore ISI started coverage on Repligen in a research note on Tuesday, March 18th. They issued an “in-line” rating and a $155.00 price target for the company. TD Cowen started coverage on Repligen in a research note on Monday, February 10th. They issued a “buy” rating and a $200.00 price target for the company. JPMorgan Chase & Co. increased their price target on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, February 21st. Finally, Canaccord Genuity Group dropped their price target on Repligen from $170.00 to $150.00 and set a “hold” rating for the company in a research note on Wednesday, April 16th. Six research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $174.58.

Repligen Stock Down 2.9 %

NASDAQ RGEN opened at $139.43 on Monday. The business has a fifty day moving average price of $139.19 and a two-hundred day moving average price of $145.93. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. Repligen has a fifty-two week low of $102.97 and a fifty-two week high of $182.52. The stock has a market capitalization of $7.83 billion, a PE ratio of -273.39, a PEG ratio of 4.54 and a beta of 1.27.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, topping the consensus estimate of $0.35 by $0.04. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. During the same quarter in the previous year, the firm earned $0.28 earnings per share. The firm’s quarterly revenue was up 10.4% compared to the same quarter last year. Equities analysts expect that Repligen will post 1.72 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Repligen news, Director Margaret Pax purchased 250 shares of the company’s stock in a transaction on Monday, March 17th. The shares were purchased at an average cost of $150.69 per share, with a total value of $37,672.50. Following the completion of the purchase, the director now owns 1,043 shares in the company, valued at $157,169.67. This represents a 31.53 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Repligen

Several institutional investors have recently added to or reduced their stakes in RGEN. Price T Rowe Associates Inc. MD lifted its stake in Repligen by 11.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company’s stock valued at $1,027,165,000 after buying an additional 743,815 shares during the period. Point72 Asset Management L.P. raised its position in shares of Repligen by 183.1% during the fourth quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company’s stock worth $132,227,000 after purchasing an additional 594,189 shares during the period. Groupama Asset Managment raised its position in shares of Repligen by 12,321.0% during the fourth quarter. Groupama Asset Managment now owns 403,932 shares of the biotechnology company’s stock worth $58,142,000 after purchasing an additional 400,680 shares during the period. Alyeska Investment Group L.P. acquired a new position in shares of Repligen during the fourth quarter worth approximately $53,428,000. Finally, Raymond James Financial Inc. acquired a new position in shares of Repligen during the fourth quarter worth approximately $52,492,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.